Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024
October 11, 2024 15:59 ET
|
Tevogen Bio Inc
Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024
Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID
October 11, 2024 12:12 ET
|
Tevogen Bio Inc
Developing therapeutic products that not only treat cancer but also enable oncology patients to maintain uninterrupted therapy.Expanding its pipeline to include non-oncology products, an opportunistic...
Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress
September 26, 2024 07:00 ET
|
Mural Oncology, Inc.
Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal...
[Latest] Global Specialty Coffee Market Size/Share Worth USD 60,953.1 Million by 2033 at a 10.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
August 13, 2024 07:30 ET
|
Custom Market Insights
Austin, TX, USA, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Specialty Coffee Market Size, Trends and Insights By Coffee Type (Single-origin...
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
June 12, 2024 16:01 ET
|
Barinthus Biotherapeutics
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
Azuria Announces Acquisition of Infrastructure Services Group LLC and Subsidiaries
June 11, 2024 10:36 ET
|
Azuria Water Solutions
Azuria Announces Acquisition of Infrastructure Services Group LLC and Subsidiaries
AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in Partnership with Boehringer Ingelheim
June 03, 2024 08:14 ET
|
AUROBAC THERAPEUTICS
AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June 3, 2024 AUROBAC THERAPEUTICS, a...
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
May 23, 2024 17:00 ET
|
Mural Oncology, Inc.
ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3...
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 07:00 ET
|
Mural Oncology, Inc.
Mural Oncology reiterates cash runway projection into 4Q 2025, with sufficient capital to fund key clinical readouts.
Aegion Rebrands as Azuria Water Solutions, Signaling a New Era in Water Infrastructure Solutions
April 25, 2024 13:58 ET
|
Azuria Water Solutions
Aegion Corporation today announced its official rebrand to Azuria Water Solutions, the leading provider of technology-enabled products and services.